Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure

Mary Ann Rose, I. Craig Henderson, Rebecca Gelman, John Boyages, Stacey M. Gore, Steven Come, Barbara Silver, Abram Recht, James L. Connolly, Stuart J. Schnitt, C. Norman Coleman, Jay R. Harris

Research output: Contribution to journalArticle

Abstract

The use of adjuvant chemotherapy in premenopausal breast cancer patients with positive nodes is now routine, but the optimal local treatment of these patients is uncertain. To determine the effect of adjuvant chemotherapy on the likelihood of local recurrence as the first site of failure in premenopausal patients treated with conservative surgery (CS) and radiotherapy (RT), we examined the outcome of 74 patients treated with CS, RT, and adjuvant chemotherapy and compared it to the outcome in 192 patients treated with CS and RT alone. Adjuvant chemotherapy consisted of four or more cycles of either a doxorubicin-containing regimen or cyclophosphamide, methotrexate, and 5-fluorouracil. All patients were less than 50 years old, had UICC-AJCC Stage I or II breast cancer treated between 1968 and 1981, had gross excision of the primary tumor, and had a total radiation dose to the primary tumor bed of ≥6000 cGy. Factors predicting for local recurrence, such as extensive intraductal carcinoma and age less than 35, were equivalent in the two groups. Women treated with adjuvant chemotherapy had significantly worse T- and N-stages than women treated with conservative surgery and radiotherapy alone: 61% versus 36% had T2 tumors (p = 0.0003), 34% versus 6% had clinically positive nodes (p <0.0001), and 97% versus 4% had pathologically positive nodes (p <0.0001). Despite the poorer prognosis of patients treated with adjuvant chemotherapy, within 5 years of diagnosis, 4% of patients who received adjuvant chemotherapy had their initial relapse in the breast and 24% had initial failure elsewhere, compared with 15% local failure first and 14% failure elsewhere first for those treated without chemotherapy (p = 0.01). We conclude that premenopausal patients with positive nodes treated with combined modality therapy (conservative surgery, radiation therapy, and adjuvant chemotherapy) have a low risk of local recurrence as a first site of failure. These results suggest a possible interaction between radiation therapy and chemotherapy in their effects on local tumor control.

Original languageEnglish (US)
Pages (from-to)711-717
Number of pages7
JournalInternational Journal of Radiation Oncology, Biology, Physics
Volume17
Issue number4
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

chemotherapy
Adjuvant Chemotherapy
surgery
breast
radiation therapy
Radiotherapy
cancer
Breast Neoplasms
tumors
Recurrence
Neoplasms
Drug Therapy
Combined Modality Therapy
Carcinoma, Intraductal, Noninfiltrating
prognosis
Methotrexate
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast

Keywords

  • Adjuvant chemotherapy
  • Breast cancer
  • Local recurrence
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure. / Rose, Mary Ann; Craig Henderson, I.; Gelman, Rebecca; Boyages, John; Gore, Stacey M.; Come, Steven; Silver, Barbara; Recht, Abram; Connolly, James L.; Schnitt, Stuart J.; Norman Coleman, C.; Harris, Jay R.

In: International Journal of Radiation Oncology, Biology, Physics, Vol. 17, No. 4, 1989, p. 711-717.

Research output: Contribution to journalArticle

Rose, MA, Craig Henderson, I, Gelman, R, Boyages, J, Gore, SM, Come, S, Silver, B, Recht, A, Connolly, JL, Schnitt, SJ, Norman Coleman, C & Harris, JR 1989, 'Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure', International Journal of Radiation Oncology, Biology, Physics, vol. 17, no. 4, pp. 711-717. https://doi.org/10.1016/0360-3016(89)90056-4
Rose, Mary Ann ; Craig Henderson, I. ; Gelman, Rebecca ; Boyages, John ; Gore, Stacey M. ; Come, Steven ; Silver, Barbara ; Recht, Abram ; Connolly, James L. ; Schnitt, Stuart J. ; Norman Coleman, C. ; Harris, Jay R. / Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure. In: International Journal of Radiation Oncology, Biology, Physics. 1989 ; Vol. 17, No. 4. pp. 711-717.
@article{762a5c4f8eb44e6692d7242cb5401aff,
title = "Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure",
abstract = "The use of adjuvant chemotherapy in premenopausal breast cancer patients with positive nodes is now routine, but the optimal local treatment of these patients is uncertain. To determine the effect of adjuvant chemotherapy on the likelihood of local recurrence as the first site of failure in premenopausal patients treated with conservative surgery (CS) and radiotherapy (RT), we examined the outcome of 74 patients treated with CS, RT, and adjuvant chemotherapy and compared it to the outcome in 192 patients treated with CS and RT alone. Adjuvant chemotherapy consisted of four or more cycles of either a doxorubicin-containing regimen or cyclophosphamide, methotrexate, and 5-fluorouracil. All patients were less than 50 years old, had UICC-AJCC Stage I or II breast cancer treated between 1968 and 1981, had gross excision of the primary tumor, and had a total radiation dose to the primary tumor bed of ≥6000 cGy. Factors predicting for local recurrence, such as extensive intraductal carcinoma and age less than 35, were equivalent in the two groups. Women treated with adjuvant chemotherapy had significantly worse T- and N-stages than women treated with conservative surgery and radiotherapy alone: 61{\%} versus 36{\%} had T2 tumors (p = 0.0003), 34{\%} versus 6{\%} had clinically positive nodes (p <0.0001), and 97{\%} versus 4{\%} had pathologically positive nodes (p <0.0001). Despite the poorer prognosis of patients treated with adjuvant chemotherapy, within 5 years of diagnosis, 4{\%} of patients who received adjuvant chemotherapy had their initial relapse in the breast and 24{\%} had initial failure elsewhere, compared with 15{\%} local failure first and 14{\%} failure elsewhere first for those treated without chemotherapy (p = 0.01). We conclude that premenopausal patients with positive nodes treated with combined modality therapy (conservative surgery, radiation therapy, and adjuvant chemotherapy) have a low risk of local recurrence as a first site of failure. These results suggest a possible interaction between radiation therapy and chemotherapy in their effects on local tumor control.",
keywords = "Adjuvant chemotherapy, Breast cancer, Local recurrence, Radiotherapy",
author = "Rose, {Mary Ann} and {Craig Henderson}, I. and Rebecca Gelman and John Boyages and Gore, {Stacey M.} and Steven Come and Barbara Silver and Abram Recht and Connolly, {James L.} and Schnitt, {Stuart J.} and {Norman Coleman}, C. and Harris, {Jay R.}",
year = "1989",
doi = "10.1016/0360-3016(89)90056-4",
language = "English (US)",
volume = "17",
pages = "711--717",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Premenopausal breast cancer patients treated with conservative surgery, radiotherapy and adjuvant chemotherapy have a low risk of local failure

AU - Rose, Mary Ann

AU - Craig Henderson, I.

AU - Gelman, Rebecca

AU - Boyages, John

AU - Gore, Stacey M.

AU - Come, Steven

AU - Silver, Barbara

AU - Recht, Abram

AU - Connolly, James L.

AU - Schnitt, Stuart J.

AU - Norman Coleman, C.

AU - Harris, Jay R.

PY - 1989

Y1 - 1989

N2 - The use of adjuvant chemotherapy in premenopausal breast cancer patients with positive nodes is now routine, but the optimal local treatment of these patients is uncertain. To determine the effect of adjuvant chemotherapy on the likelihood of local recurrence as the first site of failure in premenopausal patients treated with conservative surgery (CS) and radiotherapy (RT), we examined the outcome of 74 patients treated with CS, RT, and adjuvant chemotherapy and compared it to the outcome in 192 patients treated with CS and RT alone. Adjuvant chemotherapy consisted of four or more cycles of either a doxorubicin-containing regimen or cyclophosphamide, methotrexate, and 5-fluorouracil. All patients were less than 50 years old, had UICC-AJCC Stage I or II breast cancer treated between 1968 and 1981, had gross excision of the primary tumor, and had a total radiation dose to the primary tumor bed of ≥6000 cGy. Factors predicting for local recurrence, such as extensive intraductal carcinoma and age less than 35, were equivalent in the two groups. Women treated with adjuvant chemotherapy had significantly worse T- and N-stages than women treated with conservative surgery and radiotherapy alone: 61% versus 36% had T2 tumors (p = 0.0003), 34% versus 6% had clinically positive nodes (p <0.0001), and 97% versus 4% had pathologically positive nodes (p <0.0001). Despite the poorer prognosis of patients treated with adjuvant chemotherapy, within 5 years of diagnosis, 4% of patients who received adjuvant chemotherapy had their initial relapse in the breast and 24% had initial failure elsewhere, compared with 15% local failure first and 14% failure elsewhere first for those treated without chemotherapy (p = 0.01). We conclude that premenopausal patients with positive nodes treated with combined modality therapy (conservative surgery, radiation therapy, and adjuvant chemotherapy) have a low risk of local recurrence as a first site of failure. These results suggest a possible interaction between radiation therapy and chemotherapy in their effects on local tumor control.

AB - The use of adjuvant chemotherapy in premenopausal breast cancer patients with positive nodes is now routine, but the optimal local treatment of these patients is uncertain. To determine the effect of adjuvant chemotherapy on the likelihood of local recurrence as the first site of failure in premenopausal patients treated with conservative surgery (CS) and radiotherapy (RT), we examined the outcome of 74 patients treated with CS, RT, and adjuvant chemotherapy and compared it to the outcome in 192 patients treated with CS and RT alone. Adjuvant chemotherapy consisted of four or more cycles of either a doxorubicin-containing regimen or cyclophosphamide, methotrexate, and 5-fluorouracil. All patients were less than 50 years old, had UICC-AJCC Stage I or II breast cancer treated between 1968 and 1981, had gross excision of the primary tumor, and had a total radiation dose to the primary tumor bed of ≥6000 cGy. Factors predicting for local recurrence, such as extensive intraductal carcinoma and age less than 35, were equivalent in the two groups. Women treated with adjuvant chemotherapy had significantly worse T- and N-stages than women treated with conservative surgery and radiotherapy alone: 61% versus 36% had T2 tumors (p = 0.0003), 34% versus 6% had clinically positive nodes (p <0.0001), and 97% versus 4% had pathologically positive nodes (p <0.0001). Despite the poorer prognosis of patients treated with adjuvant chemotherapy, within 5 years of diagnosis, 4% of patients who received adjuvant chemotherapy had their initial relapse in the breast and 24% had initial failure elsewhere, compared with 15% local failure first and 14% failure elsewhere first for those treated without chemotherapy (p = 0.01). We conclude that premenopausal patients with positive nodes treated with combined modality therapy (conservative surgery, radiation therapy, and adjuvant chemotherapy) have a low risk of local recurrence as a first site of failure. These results suggest a possible interaction between radiation therapy and chemotherapy in their effects on local tumor control.

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - Local recurrence

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0024440091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024440091&partnerID=8YFLogxK

U2 - 10.1016/0360-3016(89)90056-4

DO - 10.1016/0360-3016(89)90056-4

M3 - Article

C2 - 2777660

AN - SCOPUS:0024440091

VL - 17

SP - 711

EP - 717

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -